CODX Company Profile and Key Details

Q: Who are the executives of CODX?

Mr. Reed L. BensonGen. CounselDr. Brent C. Satterfield Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Mark Poritz Ph.D.Chief Scientific OfficerMr. Andrew BensonHead of Investor RelationsMr. Cameron GundryHead of Commercialization LATAM/EURMr. Dwight H. EganChairman, Chief Executive Officer & PresMr. Brian L. Brown CPAChief Financial Officer & Company Sec.Mr. Dan Bohrer CPAVice President of Fin. & AccountingDr. Mayuranki AlmaulaSenior Vice President of Overseas Operations & Strategic AlliancesMr. Brian L. Brown C.P.A.Chief Financial Officer & Company Sec.

NASDAQ : CODX

Co-Diagnostics

$0.26

-0.0034-1.29%

Open: 2:53 PM

64.55

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Co-Diagnostics, Inc. (CODX) stock declined over -1.29%, trading at $0.26 on NASDAQ, down from the previous close of $0.26. The stock opened at $0.26, fluctuating between $0.25 and $0.27 in the recent session.

Stock Snapshot

0.2639

Prev. Close

8.82M

Market Cap

0.2537

Day Low

-0.27

P/E Ratio

-0.98

EPS (TTM)

-0.75

Cash Flow per Share

0.26

Open

33.86M

Number of Shares

0.2694

Day High

93.27%

Free Float in %

2.75

Book Value

966.48K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	0.29	0.29	0.26	0.26	2.13M
Dec 17, 2025	0.26	0.28	0.26	0.26	1.81M
Dec 16, 2025	0.27	0.28	0.24	0.25	2.78M
Dec 15, 2025	0.34	0.34	0.27	0.27	3.34M
Dec 12, 2025	0.35	0.36	0.33	0.34	1.19M
Dec 11, 2025	0.35	0.36	0.35	0.35	529.26K
Dec 10, 2025	0.36	0.37	0.35	0.36	1.26M
Dec 09, 2025	0.36	0.37	0.34	0.36	1.24M
Dec 08, 2025	0.37	0.37	0.34	0.35	1.93M
Dec 05, 2025	0.40	0.40	0.37	0.37	823.42K
Dec 04, 2025	0.36	0.41	0.34	0.39	2.45M
Dec 03, 2025	0.36	0.37	0.35	0.36	966.75K
Dec 02, 2025	0.36	0.37	0.34	0.35	996.93K
Dec 01, 2025	0.37	0.38	0.35	0.36	898.28K
Nov 28, 2025	0.36	0.39	0.36	0.37	934.71K
Nov 26, 2025	0.33	0.42	0.33	0.37	5.03M
Nov 25, 2025	0.34	0.34	0.32	0.33	761.76K
Nov 24, 2025	0.35	0.35	0.32	0.33	1.3M
Nov 21, 2025	0.34	0.35	0.32	0.35	946.63K
Nov 20, 2025	0.34	0.36	0.32	0.32	1.17M

Contact Details

Salt Lake City, UT 84109

United States

https://www.codiagnostics.com 801 438 1036

About Company

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Peers

BRKRP

10.33+2.95%

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A$360.16 SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 PODD

-3.26-1.11%

Insulet Corporation$289.62 UFPT

4.54+2.02%

UFP Technologies, Inc.$229.40 IRTC

5.69+3.38%

iRhythm Technologies, Inc.$174.17 ALGN

-3.75-2.32%

Align Technology, Inc.$157.69 TMDX

6.6+5.45%

TransMedics Group, Inc.$127.67 IRMD

0.85+0.88%

IRadimed Corporation$97.19 NARI

Inari Medical, Inc.$79.97 ESTA

4.825+6.93%

Establishment Labs Holdings Inc.$74.42

Company Overview

The stock is currently mid-range between its 52-week high and low $0.23 and $1.55. With a market capitalization of about $8.82 million, Co-Diagnostics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.16). Key stats such as the average daily volume over the past year has been around 20.82 million shares, volume is running light vs its 52-week average. Headquartered in Salt Lake City, UT, Co-Diagnostics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Dwight H. Egan, the company employs approximately 132 people and listed since July 12, 2017. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

Technical Performance

CODX has shown weak momentum, losing -24.25% over the past week and -39.74% over the past quarter, though year-to-date performance is down -64.81%. Short-term trend indicators are mixed aligned (SMA20 -20.72%, SMA50 -30.51%, SMA200 -23.03%). The stock’s 14-day RSI is 39.62 (weak momentum), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.97% below its high and over 16.0% above its low. Average 10-day trading volume of 2.25 million shares is below the 3-month average of 20.49 million, indicating normal recent market interest.

Valuation Metrics

Co-Diagnostics, Inc. trades at a P/E ratio of -0.31, slightly below the S&P 500 average, with a price-to-sales ratio of 17.59 and a price-to-book ratio of 0.25 suggesting the stock is closer to book value. The P/FCF stands at -0.28, also above market averages.

Dividend & Fair Value

Co-Diagnostics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.06. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Co-Diagnostics, Inc. generated EPS of -$0.96 over the past year. Five-year average earnings growth is -27.4%. Wall Street analysts project EPS growth of 31.42% annually over the next five years. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at -$0.12. Next year's EPS is expected at -$11.11. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $1.00. The high target offers 3746.15% upside. The low target suggests 284.62% downside. The mean target is $4.50. This offers 1630.77% upside. Co-Diagnostics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 13, 2025, missed forecasts by -15.79%. The prior quarter beat by -8.0%. Over the last six quarters, Apple has recorded several small beats. These include -26.47% in August 08, 2024.

Shareholding & Insider Activity

Co-Diagnostics, Inc. has 38.52 million shares outstanding. The public float is 35.89 million shares, elevated short interest at 3.79% of float. This equals 1.36 million shares. The short ratio is 0.3 days. Institutional investors hold 14.61% of the float. Insiders own 7.88%. Satterfield Brent holds 2.28 million shares, Brown Brian Lee has 76.24 thousand shares and SERBIN RICHARD S has 2.50 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Co-Diagnostics generated $991.47K in revenue, or $0.03 per share. Gross margin was -446.20%, operating margin -4894.41%, and net profit margin -3563.67%. Returns are negative, with ROA at -34.09% and ROE at -41.08%.
On valuation metrics, Co-Diagnostics trades at a P/E of -0.31, P/S of 17.59 and P/B of 0.25. The current ratio is 3.81 and quick ratio is 3.51. Operationally, the company’s inventory turnover is 0.31 and cash conversion cycle is -361.20 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of -21.17.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Co-Diagnostics posted revenue of $991.47K, down slightly from $34.22M in the prior quarter. Gross profit was - $4.42M (margin -446.20%). Operating income was - $48.53M (margin -4894.4%). Net income was- $35.33M (EPS - $1.20).
The company ended the quarter with $58.55M in cash and short-term investments, a total debt of $2.99M, and net debt of - $11.93M. Total assets were $103.65M, with equity of $86.01M. Financials further reflected weakness, with operating cash flow of - $22.08M, free cash flow of - $23.45M, and capital expenditures of - $1.37M.

Price Forecast & Outlook

Our AI price prediction model suggests that Co-Diagnostics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.85%, with price expected at $0.23 by January 02, 2026, within a range of $0.20 to $0.27 3-Month Outlook: Projected fall of -5.27%, reaching $0.25 by March 19, 2026, with a range of $0.22 to $0.29. 1-Year Outlook: Projected gain of 244.83%, with price at $0.91 by December 18, 2026, within a range of $0.00 to $0.73.

Key Takeaways

Co-Diagnostics, Inc. (NASDAQ:CODX) shares are down -64.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Co-Diagnostics, Inc. trading at a premium to the broader market with a P/E of -0.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.19, suggesting 2624.52% upside. Our AI forecast model points to short-term weakness (-12.85% over two weeks), a medium-term fall (-5.27% over three months), and a longer-term gain (244.83% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Co-Diagnostics, Inc. (CODX) stock price?

Co-Diagnostics, Inc. (NASDAQ: CODX) stock price is $0.26 in the last trading session. During the trading session, CODX stock reached the peak price of $0.27 while $0.25 was the lowest point it dropped to. The percentage change in CODX stock occurred in the recent session was -1.29% while the dollar amount for the price change in CODX stock was - $0.00.

CODX's industry and sector of operation?

The NASDAQ listed CODX is part of Medical - Devices industry that operates in the broader Healthcare sector. Co-Diagnostics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CODX?

Mr. Reed L. Benson
Gen. Counsel
Dr. Brent C. Satterfield Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Mark Poritz Ph.D.
Chief Scientific Officer
Mr. Andrew Benson
Head of Investor Relations
Mr. Cameron Gundry
Head of Commercialization LATAM/EUR
Mr. Dwight H. Egan
Chairman, Chief Executive Officer & Pres
Mr. Brian L. Brown CPA
Chief Financial Officer & Company Sec.
Mr. Dan Bohrer CPA
Vice President of Fin. & Accounting
Dr. Mayuranki Almaula
Senior Vice President of Overseas Operations & Strategic Alliances
Mr. Brian L. Brown C.P.A.
Chief Financial Officer & Company Sec.

How CODX did perform over past 52-week?

CODX's closing price is 15.75% higher than its 52-week low of $0.23 where as its distance from 52-week high of $1.55 is -82.97%.

How many employees does CODX have?

Number of CODX employees currently stands at 132.

Link for CODX official website?

Official Website of CODX is: https://www.codiagnostics.com

How do I contact CODX?

CODX could be contacted at phone 801 438 1036 and can also be accessed through its website. CODX operates from 2401 South Foothill Drive, Salt Lake City, UT 84109, United States.

How many shares of CODX are traded daily?

CODX stock volume for the day was 966.48K shares. The average number of CODX shares traded daily for last 3 months was 20.82M.

What is the market cap of CODX currently?

The market value of CODX currently stands at $8.82M with its latest stock price at $0.26 and 33.86M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	132
Beta	1.16
Sales or Revenue	$991.47K
5Y Sales Change%	71.611%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

CODX Company Profile and Key Details

Co-Diagnostics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Shareholding & Insider Activity

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Valuation Metrics